Uquifa is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical Industry. Operates 3 manufacturing sites, 2 in Spain and 1 in Mexico, which operate under cGMP conditions and have been inspected and approved by major Pharmaceutical Companies and Regulatory Authorities, including the US FDA.
Uquifa sells to more than 70 countries worldwide and has more than 150 active DMF´s filed and 20 COS approved. Uquifa counts amongst its customers the major Generic and Ethical companies operating in the Industry and continues to invest in personnel and facilities to maintain a arrow technology offering to both, the Generic Industry and the Ethical Pharmaceutical Industry.
- 1936 UQUIFA was founded to supply local Spanish pharmacies and was the first manufacturer of the antibiotic Penicillin in Spain. In less than ten years, UQUIFA became the largest Spanish Penicillin producer.
1948 The Spanish government declared Penicillin production of national interest and a group of laboratories (including UQUIFA) were created becoming the company Antibióticos S.A. This company obtained the exclusive concession for Penicillin production in Spain.
1991 UQUIFA was acquired by Holliday Chemical Holdings, an UK based chemical company. The purchase included the Llica de Vall production site and the offices located in Barcelona. UQUIFA had been classified as a pharmaceutical laboratory but in the late 1980s it was decided to focus the business on the manufacture of APIs for the pharmaceutical and veterinary markets.
1992 Acquisition of the Sant Celoni site in Spain UQUIFA aquired the company Barisintex with its headquarters and facilities in Sant Celoni, near Barcelona, widening production capability. This acquisition further consolidated Uquifa´s position as a major supplier of Ranitidine and Cimetidine to the Generics industry. Aslo during the mid- 1990s,Uquifa expanded its business base by providing contract manufacturing services to the Pharmaceutical Industry. Gradually Uquifa´s customer list grew to include many of the largest pharmaceutical companies in the world. *
1997/8 Acquisition of the Mexican site UQUIFA acquired a new chemical plant. The SKB (SmithKlineBecham) facility is placed in Cuernavaca, near Mexico DC. This last acquisition established the 3 manufacturing locations which Uquifa operates today. * 1998 Holliday Chemical Holdings was acquired by the group Yule Catto plc. UQUIFA was the pharmaceutical division of Yule Catto plc and remained headquartered in Barcelona,Spain.
2011 Uquifa was acqquired by Vivimed Labs, an India base chemical group. The purchase includes the facilities of Uquifa in Spain and Mexico. Uquifa´s focus remains on supplying APIs to the Generics industry as well providing contract manufacturing services to the Pharmaceutical industry. Uquifa continues to invest heavily in R&D, the latest being the building of an R&D centre at the Sant Celoni site in Spain and a new Pilot Plant. These facilities were commissioned in 2005.
2012 Uquifa SA announces the creation of QSynth SA as its independent commercial subsidiary, with the primary mission to manage and improve its services for the CMO business to the Pharmaceutical Industry.